Newer Immunotherapies for the Treatment of Acute Neuromuscular Disease in the Critical Care Unit

Opinion statementPurpose of reviewIn this review, we discuss current treatment options for commonly encountered neuromuscular disorders in intensive care units. We will discuss epidemiology, pathophysiology, and acute and chronic treatment options for myasthenia gravis, Guillain-Barr é syndrome, West Nile virus, Botulism, and amyotrophic lateral sclerosis.Recent findingsEculizumab is the newest immunomodulator therapy approved by the Food and Drug Administration in treatment of myasthenia gravis, shown to improve long-term functional outcomes. Edaravone is the newest therapy in management of amyotrophic lateral sclerosis, shown to slow functional deterioration. Efgartigimod showed great promise in a phase 2 safety and efficacy trial in the treatment of stable generalized myasthenia gravis. Eculizumab was found to be safe in a small phase 2 trial for use in Guillain-Barr é syndrome.SummaryCurrently, therapies such as plasma exchange, intravenous immunoglobulins, and steroids remain the mainstay of treatment in the ICU for many neuromuscular disorders. While there are some newer immunotherapies available, few have been studied in the acute setting. However, with the advent of new immunotherapies and biologics, changes in these approaches may be on the horizon.
Source: Current Treatment Options in Neurology - Category: Neurology Source Type: research

Related Links:

We describe the principles of imaging host T-cells and adoptively transferred therapeutic T-cells as well as the value of traceable cancer cell models in immunotherapy development. Our emphasis is on in vivo cell tracking methodology, including important aspects and caveats specific to immunotherapies. We discuss a variety of associated experimental design aspects including parameters such as cell type, observation times and intervals, and detection sensitivity. The focus is on preclinical cell tracking but aspects relevant for clinical translation are also discussed.
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Publication date: Available online 2 April 2020Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Yuliya Afinogenova, Tamar Rubin, Sagar Patel, Rachel Powell, Janina Gilo, Morgan Denno, Gary Soffer, Jason Lee, Louis Mendelson, Jeffrey Factor
Source: The Journal of Allergy and Clinical Immunology: In Practice - Category: Allergy & Immunology Source Type: research
Contributors : Dawn S Lin ; Luyi Tian ; Daniela Amann-Zalcenstein ; Tracey M Baldwin ; Shalin H NaikSeries Type : Expression profiling by high throughput sequencingOrganism :Flt3 ligand (Flt3L) promotes an increased generation of type 1 conventional dendritic cells (cDC1s), resulting in enhanced immunity against infections and cancer. Here, we employ cellular barcoding to understand how Flt3L regulates single haematopoietic stem and progenitor cell (HSPC) fate. Our results demonstrate that although Flt3L stimulation can recruit some additional cDC1-generating HSPCs, the major contributing factor to higher cDC1 numbers is t...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Source Type: research
Cancer immunotherapy has reached a critical point, now that immune checkpoint inhibitors and two CAR-T products have received market approval in treating 16 types of cancers and 1 tissue-agnostic cancer indica...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Tags: Review Source Type: research
Immunotherapy with immune checkpoint inhibitors (ICIs) for solid tumors had significantly improved overall survival. This type of therapy is still not available for acute myeloid leukemia (AML). One major issu...
Source: Journal of Hematology and Oncology - Category: Hematology Authors: Tags: Letter to the Editor Source Type: research
ie Lei Wang Neuro-degenerative disease is a common progressive nervous system disorder that leads to serious clinical consequences. Gait rhythm dynamics analysis is essential for evaluating clinical states and improving quality of life for neuro-degenerative patients. The magnitude of stride-to-stride fluctuations and corresponding changes over time—gait dynamics—reflects the physiology of gait, in quantifying the pathologic alterations in the locomotor control system of health subjects and patients with neuro-degenerative diseases. Motivated by algebra topology theory, a topological data analysis...
Source: Sensors - Category: Biotechnology Authors: Tags: Article Source Type: research
AbstractOn-treatment steroids for countering immune checkpoint inhibitor-induced inflammatory responses (irAEs) are a hallmark of cancer immunotherapy. However, the suppressive nature of steroids has raised questions regarding their ability to compromise the function of the ‘proliferative burst’ of effector T cells induced by immune checkpoint antibodies. We investigated the effector functions and the co-inhibitory receptor profile of stimulated peripheral blood mononuclear cells (PBMCs) pre-treated with prednisone and dexamethasone alone or in the presence of anti -PD-1/CTLA-4 antibodies. Also, clinical analys...
Source: Cancer Immunology, Immunotherapy - Category: Cancer & Oncology Source Type: research
adid Failloux : Vector competence is an important parameter in evaluating whether a species plays a role in transmission of an arbovirus. Although the protocols are similar, interpretation of results is unique given the specific interactions that exist between a mosquito population and a viral genotype. Here, we assessed the infection (IR), dissemination (DR), and transmission (TR) rates of Cx. pipiens s.l., collected from Iran, for West Nile virus (WNV) lineage 1a. We showed that Cx. pipiens s.l. mosquitoes in Iran were susceptible to WNV with IR up to 89.7%, 93.6%, and 83.9% at 7, 14, and 21 days post-infection (d...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
Immunotherapies harnessing T cell immunity have shown remarkable clinical success for the management of cancer. However, only a proportion of patients benefit from these treatments. The presence of type I interferon (IFN) within the tumor microenvironment is critical for driving effective tumor-specific T cell immunity. Individuals can produce 12 distinct subtypes of IFNα, which all signal through a common receptor. Despite reported differences in anti-viral potencies, the concept that distinct IFNα subtypes can improve anti-cancer treatments remains unclear. We tested whether expression of unique IFNα su...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
The interaction of lymphoma cells with their microenvironment has an important role in disease pathogenesis and is being actively pursued therapeutically using immunomodulatory drugs, including immune checkpoint inhibitors. Diffuse large B-cell lymphoma (DLBCL) is an aggressive high-grade disease that remains incurable in ~40% of patients treated with R-CHOP immunochemotherapy. The FOXP1 transcription factor is abundantly expressed in such high-risk DLBCL and we recently identified its regulation of immune response signatures, in particular, its suppression of the cell surface expression of major histocompatibility class I...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: ALS | Botulism | Brain | Epidemiology | Food and Drug Administration (FDA) | Guillain-Barr Syndrome | Immunotherapy | Intensive Care | Myasthenia Gravis | Neurology | West Nile Virus